Clinical trials: First-line Treatment
Lymphoma
GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00896519
- Testing
- rituximab, sargramostim, cyclophosphamide
- Volunteers
- 30 people
- Sponsor
- French Innovative Leukemia Organisation
NSCLC (non-small Cell Lung Cancer)
First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy
Induction phase of carboplatin+etoposide+pembrolizumab followed by maintenance of Pembrolizumab+sacituzumab govitecan
- Trial name
- NCT06667167
- Testing
- Induction Carboplatin
- Where
- Israel
- Volunteers
- 21 people
- Sponsor
- Nir Peled
Breast Cancer, Metastatic Cancer
Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02
This study is a prospective, open-label, phase II clinical study for patients with HR+/HER2- advanced breast cancer.
- Trial name
- NCT05205200
- Testing
- SHR-1316, SHR6390, Nab paclitaxel
- Where
- China
- Volunteers
- 338 people
- Sponsor
- Fudan University
Cervical Cancer Recurrent or Persistent, Palliative Treatment
Combination of Nimotuzumab Cisplatin-Vinorelbine in First Line Chemotherapy in Recurring-Persistent Cervical Carcinoma
This study evauates the global survival of patients following administration of mAb Nimotuzumab hR3 + chemotherapy in the treatment of cervical cancer in first line therapy, after relapsing from chemo-radiotherapy.
- Conditions
- Cervical Cancer Recurrent or Persistent, Palliative Treatment, Monoclonal Antibody in Cervical Cancer Treatment
- Trial name
- NCT02083211
- Testing
- mAb Nimotuzumab
- Where
- Mexico
- Volunteers
- 168 people
- Sponsor
- National Institute of Cancerología
Head and Neck Neoplasms
Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )
This study will test an investigational study drug called patritumab. It is a 'randomized study' which means participants have an equal chance of being assigned to receive the experimental medication (patritumab) or a substance…
- Trial name
- NCT02633800
- Testing
- Patritumab, Cetuximab, Cisplatin
- Where
- 34 sites in Belgium, France and 5 more
- Volunteers
- 87 people
- Sponsor
- Daiichi Sankyo
Breast Cancer Stage IV
Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer
This study is designed to comprehensively evaluate the HER2 positive recurrent/metastatic breast cancer patients in the real world who receive the combination of Inetetamab and Paclitaxel ± Pertuzumab, including basic…
- Trial name
- NCT06578299
- Testing
- Inetetamab and Paclitaxel ± Pertuzumab
- Volunteers
- 100 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma, Transarterial Chemoembolization
Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma
This study aims to evaluate the safety and effectiveness of a combined treatment for patients with unresectable hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery.
- Trial name
- NCT07281664
- Testing
- Transarterial chemoembolization (TACE), bevacizumab and atezolizumab
- Volunteers
- 30 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Carcinoma, Non-Small-Cell Lung
Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma
Phase I study. To determine the MTD (Maximum Tolerated Dose) of nintedanib + weekly Docetaxel in patients with locally advanced or metastatic lung adenocarcinoma after failure of platinum-based first line chemotherapy.
- Trial name
- NCT02668393
- Testing
- Docetaxel, Nintedanib
- Where
- 4 sites in France, Germany
- Volunteers
- 14 people
- Sponsor
- Boehringer Ingelheim
Small Cell Lung Cancer (SCLC)
A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
The purpose of this trial is to compare the effects of TAS-102 with either amrubicin or topotecan (drugs used in Small Cell Lung Cancer) on lung cancer to find out the effects on survival, how much time may pass without disease…
- Trial name
- NCT01904253
- Testing
- TAS-102, Amrubicin (Japan), Topotecan (Japan/Europe)
- Where
- 23 sites in Germany, Italy and 1 more
- Volunteers
- 18 people
- Sponsor
- Taiho Oncology, Inc.
Hepatocellular Carcinoma (HCC)
A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
This study is a randomized, double-blind, multicenter, phase III clinical study to compare the efficacy and safety of HLX10 + HLX04 vs Sorafenibas as the First-line Treatment in Patients with Locally Advanced or Metastatic HCC…
- Trial name
- NCT04465734
- Testing
- HLX10, HLX04, Sorafenib
- Where
- China
- Sponsor
- Shanghai Henlius Biotech
Metastatic Melanoma, Immune Checkpoints Inhibitors
Biomarkers in Immunotherapy of Melanoma
Background: Immunotherapy has been successful in treating advanced melanoma, but a large proportion of patients do not respond to the treatment with immune checkpoint inhibitors (ICIs).
- Conditions
- Metastatic Melanoma, Immune Checkpoints Inhibitors, Gastrointestinal Microbiome (Bacterial and Viral), Exosomal mRNA Expression of PD-L1 and IFNγ
- Trial name
- NCT05878977
- Testing
- Immune checkpoint inhibitor
- Where
- Slovenia
- Volunteers
- 150 people
- Sponsor
- Institute of Oncology Ljubljana
Upper Respiratory Tract Infection, Influenza
A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection
To evaluate the efficacy of oseltamivir ,as compared with the placebo arm and zanamivir with its control arm with respect to symptoms duration among patients infected with influenza A (H1N1) virus.
- Trial name
- NCT00979667
- Testing
- Oseltamivir, Zanamivir
- Where
- 3 sites in China, Hong Kong
- Volunteers
- 4 people
- Sponsor
- Chinese University of Hong Kong
Colorectal Cancer
Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00544700
- Testing
- bevacizumab, no maintenance
- Where
- 29 sites in Switzerland
- Volunteers
- 265 people
- Sponsor
- Swiss Cancer Institute
Marginal Zone Lymphoma
Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
This is a multicenter prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with obinutuzumab and lenalidomide in untreated marginal zone lymphoma.
- Trial name
- NCT06454968
- Testing
- Orelabrutinib, obinutuzumab, lenalidomide
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Peking Union Medical College Hospital
HIV Infections
PREventing Progression of Adipose Tissue Redistribution
The main objective of the study is to assess changes in fat distribution over 48 weeks of treatment in patients who currently successfully use zidovudine (AZT) and lamivudine (3TC) as part of their regimen and who will either…
- Trial name
- NCT00389194
- Testing
- continuing AZT+3TC or switching AZT+3TC to TDF+ FTC
- Where
- Netherlands
- Volunteers
- 120 people
- Sponsor
- International Antiviral Therapy Evaluation Center
HER2-positive Gastric Cancer
Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer
Investigators assessed the effectiveness of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer
- Trial name
- NCT05311189
- Testing
- HLX10, Trastuzumab and Chemotherapy
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital
Marginal Zone Lymphoma(MZL)
Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
This is a single-arm, prospective clinical study to evaluate the efficacy and safety of orelabrutinib combined with rituximab as first-line systemic treatment for marginal zone lymphoma.
- Trial name
- NCT07022223
- Testing
- orelabrutinib combined with rituximab regimen
- Where
- 18 sites in China
- Volunteers
- 51 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma
Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
Antibody-drug conjugates (ADCs) have demonstrated substantial improvement in progression free survival (PFS) and overall survival (OS) in phase III clinical trials in patients with metastatic triple negative breast cancer (mTNBC)…
- Conditions
- HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Metastatic Breast Cancer, HR+ HER2 Breast Cancer
- Trial name
- ENCORE (NCT06774027)
- Testing
- Specimen collection, Non-Investigational Antibody-Drug Conjugates (ADC), Medical Record Review
- Where
- 3 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Non-Squamous Non-Small Cell Lung Cancer
An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC)
This observational study will evaluate the efficacy and safety of Tarceva (erlotinib) in first-line therapy in patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer.
- Trial name
- NCT01790217
- Where
- Germany
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
HIV-related Lymphoma, HIV Infections
High Dose Therapy and Peripheral Blood Stem Cell Transplantation in HIV Related Non Hodgkin Lymphoma (NHL) at High Risk
The purpose of the study is to evaluate the efficacy of an intensified first-line treatment, with conventional chemotherapy (CHOP) plus monoclonal antibody anti CD20, followed by high dose chemotherapy and PBSC transplantation in…
- Trial name
- HDT-HIV (NCT01045889)
- Testing
- Rituximab and CHOP regimen + PBSCT
- Where
- Italy
- Volunteers
- 27 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia